SRTS
Sensus Healthcare, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$3.19
−2.15%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 17.5M | 27.5M | 41.8M | 24.4M | 44.5M |
| Cost of Revenue | 11.1M | 15.6M | 17.4M | 10.3M | 14.9M |
| Gross Profit | 6.4M | 11.9M | 24.4M | 14.1M | 29.6M |
| Operating Expenses | |||||
| R&D Expense | 6.4M | 7.8M | 4.2M | 3.7M | 3.5M |
| SG&A Expense | 13.2M | 14.4M | 12.1M | 10.8M | 11.3M |
| General & Admin Expense | 7.5M | 7.9M | 7.1M | 5.2M | 5.0M |
| Selling & Marketing Expense | 5.7M | 6.5M | 5.0M | 5.6M | 6.3M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 19.6M | 22.2M | 16.3M | 14.4M | 14.8M |
| Cost and Expenses | 30.8M | 37.8M | 33.7M | 24.8M | 29.7M |
| Operating Income (EBIT) | (13.3M) | (10.3M) | 8.1M | (382.0K) | 14.8M |
| Non-Operating | |||||
| Interest Income | 765.0K | 683.0K | 932.0K | 992.0K | 382.0K |
| Interest Expense | — | — | — | — | 2.0K |
| Net Interest Income | 765.0K | 683.0K | 932.0K | 992.0K | 380.0K |
| Other Non-Op Income/Expense | 558.0K | 683.0K | 932.0K | 1.0M | 13.2M |
| Non-Operating Income (excl Interest) | (3.4M) | (683.0K) | (932.0K) | (1.0M) | (13.2M) |
| EBT (Pre-Tax Income) | (12.7M) | (9.6M) | 9.0M | 652.0K | 28.0M |
| Income Tax Expense | 2.8M | (1.9M) | 2.4M | 167.0K | 3.7M |
| Bottom Line | |||||
| Net Income | (15.5M) | (7.7M) | 6.6M | 485.0K | 24.2M |
| Earnings from Cont. Ops | (15.5M) | (7.7M) | 6.6M | 485.0K | 24.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (15.5M) | (7.7M) | 6.6M | 485.0K | 24.2M |
| Per Share | |||||
| Basic EPS | ($0.94) | ($0.47) | $0.41 | $0.03 | $1.47 |
| Diluted EPS | ($0.94) | ($0.47) | $0.41 | $0.03 | $1.46 |
| Revenue Per Share | $1.06 | $1.68 | $2.56 | $1.50 | $2.70 |
| Shares | |||||
| Basic Shares Outstanding | 16.5M | 16.3M | 16.3M | 16.3M | 16.5M |
| Diluted Shares Outstanding | 16.5M | 16.3M | 16.4M | 16.3M | 16.6M |
| Profitability Metrics | |||||
| EBITDA | (9.5M) | (9.2M) | 9.5M | 1.1M | 28.5M |
| D&A | 384.0K | 386.0K | 432.0K | 461.0K | 509.0K |
| EBIT | (9.9M) | (9.6M) | 9.0M | 652.0K | 28.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026